Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Endocrinol Invest ; 23(5): 321-4, 2000 May.
Artigo em Inglês | MEDLINE | ID: mdl-10882151

RESUMO

Interferon (IFN)-beta has become a widespread therapy for multiple sclerosis. As already reported for IFN-alpha, thyroid autoimmunity and dysfunctions have been observed also in course of IFN-beta therapy. Nevertheless, very few cases of Graves' disease, occurred in such condition, have been reported in literature. We here describe the case of a 40-year-old female affected by multiple sclerosis, who received IFN-beta-1b, 8 million IU s.c. every other day for her condition. After 22 months of cytokine administration, she developed a severe Graves' disease with persistently positive TR-Ab which suggested the withdrawal of the treatment. Our patient had performed a complete thyroid evaluation with normal findings, before and during the first 6 months of therapy. This case suggests that patients undergoing long-term IFN-beta therapy should be monitored for thyroid hormones and antibodies throughout the treatment as thyroidal side effect can be a late event.


Assuntos
Doença de Graves/induzido quimicamente , Interferon beta/efeitos adversos , Esclerose Múltipla/tratamento farmacológico , Adulto , Autoanticorpos/sangue , Feminino , Doença de Graves/diagnóstico , Doença de Graves/imunologia , Humanos , Interferon beta-1a , Interferon beta-1b , Interferon beta/administração & dosagem , Interferon beta/uso terapêutico , Glândula Tireoide/imunologia , Tiroxina/sangue , Tri-Iodotironina/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...